The Relationship Between Anticipated Gender Dysphoria and Intention to Use Longer-Acting Formulations of Pre-Exposure Prophylaxis for HIV in Transgender and Gender Expansive Texans
Restricted accessResearch articleFirst published online June, 2026
The Relationship Between Anticipated Gender Dysphoria and Intention to Use Longer-Acting Formulations of Pre-Exposure Prophylaxis for HIV in Transgender and Gender Expansive Texans
Longer-acting pre-exposure prophylaxis (LA PrEP) may trigger gender dysphoria in transgender and gender expansive (TGE) individuals and influence intentions to use it. This community-based participatory research project examined this relationship regarding three LA PrEP formulations. Overall, 513 TGE Texans responded to an online survey, and 410 were included in this analysis. Anticipated dysphoria was associated with lower intentions to use an annual implantable (β = −0.27, p < 0.001). Intentions to use a monthly oral and a bimonthly injectable were associated with gender identity. Including TGE individuals in the development of LA PrEP will improve uptake by identifying unique barriers.
BateganyaMH, AmanyeiweU, RoxoU, et al.Impact of support groups for people living with HIV on clinical outcomes: a systematic review of the literature. J Acquir Immune Defic Syndr, 2015; 68 (Suppl 3)(0 3):S368–S374.
3.
RowniakS. PrEP: a case study. J Am Assoc Nurse Pract, 2015; 27(6):296–299; doi: 10.1002/2327-6924.12240
4.
SpinnerCD, BoeseckeC, ZinkA, et al.HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection, 2016; 44(2):151–158; doi: 10.1007/s15010-015-0850-2
5.
SullivanPS, SieglerAJ. Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and emerging models of PrEP implementation. Sex Health, 2018; 15(6):522–527; doi: 10.1071/sh18103
6.
WoodS, GrossR, SheaJA, et al.Barriers and facilitators of PrEP adherence for young men and transgender women of color. AIDS Behav, 2019; 23(10):2719–2729; doi: 10.1007/s10461-019-02502-y
7.
CahillSR, KeatleyJ, Wade TaylorS, et al.“Some of us, we don’t know where we’re going to be tomorrow.” Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco. AIDS Care, 2020; 32(5):585–593; doi: 10.1080/09540121.2019.d1659912.e
8.
SharfsteinJM, KilleleaA, DangerfieldD. Long-acting cabotegravir for HIV prevention: issues of access, cost, and equity. JAMA, 2022; 327(10):921–922; doi: 10.1001/jama.2022.0420
9.
CoelhoLE, TorresTS, VelosoVG, et al.Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV, 2019; 6(11):e788–e799; doi: 10.1016/S2352-3018(19)30238-3
10.
CelumC, GrinsztejnB, NgureK. Preparing for long-acting PrEP delivery: building on lessons from oral PrEP. J Int AIDS Soc, 2023; 26(Suppl 2):e26103; doi: 10.1002/jia2.26103
11.
LiegeonG, GhosnJ. Long-acting injectable cabotegravir for PrEP: a game-changer in HIV prevention? HIV Med, 2023; 24(6):653–663; doi: 10.1111/hiv.13451
12.
PoteatT, RachlinK, LareS, et al.History and prevalence of gender dysphoria. In: Transgender Medicine. Contemporary Endocrinology. (PoretskyL, HembreeW eds.) Humana Press, Inc.: Totowa, NJ; 2019; pp. 1–24.
13.
GalupoMP, Pulice-FarrowL, LindleyL. “Every time I get gendered male, I feel a pain in my chest”: understanding the social context for gender dysphoria. Stigma Health, 2020; 5(2):199–208; doi: 10.1037/sah0000189
14.
DolanIJ, StraussP, WinterS, et al.Misgendering and experiences of stigma in health care settings for transgender people. Med J Aust, 2020; 212(4):150–151.e1; doi: 10.5694/mja2.50497
15.
BaldwinA, DodgeB, SchickVR, et al.Transgender and genderqueer individuals’ experiences with health care providers: what’s working, what’s not, and where do we go from here? J Health Care Poor Underserved, 2018; 29(4):1300–1318; doi: 10.1353/hpu.2018.0097
16.
LindleyL, Pulice-FarrowL, BudgeS. The antecedents of gender dysphoria and the associated thoughts, emotions, and ways of coping: a qualitative analysis and clinical implications. Couns Psychol Q, 2023; 36(4):592–614; doi: 10.1080/09515070.2022.2142201
17.
AdamsEC, VarkeyTC, AijazA, et al.Increased surveillance or increased scrutiny: curbing inappropriate screening of endometrial cancer in transgender men. J Family Reprod Health, 2022; 16(3):170–176.
18.
IsraelBA, SchulzAJ, ParkerEA, et al.Review of community-based research: assessing partnership approaches to improve public health. Annu Rev Public Health, 1998; 19:173–202; doi: 10.1146/annurev.publhealth.19.1.173
19.
TeitcherJE, BocktingWO, BauermeisterJA, et al.Detecting, preventing, and responding to “fraudsters” in internet research: ethics and tradeoffs. J Law Med Ethics, 2015; 43(1):116–133; doi: 10.1111/jlme.12200
MustanskiB, RyanDT, HayfordC, et al.Geographic and individual associations with PrEP stigma: results from the RADAR cohort of diverse young men who have sex with men and transgender women. AIDS Behav, 2018; 22(9):3044–3056; doi: 10.1007/s10461-018-2159-5
22.
IBM Corp. Released 2021. IBM SPSS Statistics for Windows, Version 29.0. IBM Corp.: Armonk, NY.
23.
RaelCT, Lopez-RíosJ, McKennaSA, et al.Transgender women’s barriers, facilitators, and preferences on tailored injection delivery strategies to administer long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP). AIDS Behav, 2021; 25(12):4180–4192; doi: 10.1007/s10461-021-03357-y
24.
RaelCT, MartinezM, GiguereR, et al.Transgender women’s concerns and preferences on potential future long-acting biomedical HIV prevention strategies: the case of injections and implanted medication delivery devices (IMDDs). AIDS Behav, 2020; 24(5):1452–1462; doi: 10.1007/s10461-019-02703-5
25.
IsraelBA, ParkerEA, RoweZ, et al.Community-based participatory research: lessons learned from the Centers for Children’s Environmental Health and Disease Prevention Research. Environ Health Perspect, 2005; 113(10):1463–1471; doi: 10.1289/ehp.7675
